Protein detail
CD4
T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4)
Entry name CD4 | UniProt ID | EVMP confidence score 0.50 |
Supporting publications (n) 5 | Transmembrane count 1 | Protein classification CD markersDisease related genesFDA approved drug targetsHuman disease related genesPredicted intracellular proteinsPredicted membrane proteinsTransporters |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information12
Protein Names
T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4)
Protein Class (7)
CD markersDisease related genesFDA approved drug targetsHuman disease related genesPredicted intracellular proteinsPredicted membrane proteinsTransporters
Protein Function (6)
- Predicted intracellular proteins
- CD markers
- Human disease related genes:Immune system diseases:Primary immunodeficiency
- Transporters:Accessory Factors Involved in Transport
- Disease related genes
- FDA approved drug targets:Biotech drugs
Transmembrane
397..418; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Description
CD4 molecule
Chromosome
12
Position
6786858-6820799
Supporting publications (n)
5
EVMP confidence score
0.50
Fluorescence & Localization3
Cell SpecificRetinal amacrine cellsSingle-Nuclei Brain Specificcerebellar inhibitory
Function & Pathway7
Protein Function (6)
- Predicted intracellular proteins
- CD markers
- Human disease related genes:Immune system diseases:Primary immunodeficiency
- Transporters:Accessory Factors Involved in Transport
- Disease related genes
- FDA approved drug targets:Biotech drugs
Cellular Component (8)
Molecular Function (17)
- GO:0001618 virus receptor activity
- GO:0004888 transmembrane signaling receptor activity
- GO:0005201 extracellular matrix structural constituent
- GO:0005515 protein binding
- GO:0008270 zinc ion binding
- GO:0008289 lipid binding
- GO:0015026 coreceptor activity
- GO:0019899 enzyme binding
- GO:0019901 protein kinase binding
- GO:0023026 MHC class II protein complex binding
Page 1 of 2
Biological Process (3)
KEGG (14)
- hsa03250 Viral life cycle - HIV-1
- KEGG:hsa03260 Virion - Human immunodeficiency virus
- KEGG:hsa04060 Cytokine-cytokine receptor interaction
- KEGG:hsa04514 Cell adhesion molecule (CAM) interaction
- KEGG:hsa04612 Antigen processing and presentation
- KEGG:hsa04640 Hematopoietic cell lineage
- KEGG:hsa04658 Th1 and Th2 cell differentiation
- KEGG:hsa04659 Th17 cell differentiation
- KEGG:hsa04660 T cell receptor signaling pathway
- KEGG:hsa05135 Yersinia infection
Page 1 of 2
Reactome (27)
- R-hsa-1280218 adaptive immune system
- R-hsa-1462054 alpha defensins
- R-hsa-6803157 antimicrobial peptides
- R-hsa-8856825 cargo recognition for clathrin mediated endocytosis
- R-hsa-8856828 clathrin mediated endocytosis
- R-hsa-389948 co inhibition by pd 1
- R-hsa-1280215 cytokine signaling in immune system
- R-hsa-1461973 defensins
- R-hsa-202424 downstream tcr signaling
- R-hsa-162594 early phase of hiv life cycle
Page 1 of 3
Mediation Categories (5)
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence144
Enzyme-Mediated Modification (3)
3 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| CD4 | PRKCA | P17252 | S | 440 | phosphorylation | PhosphoSite_MIMPMIMPProtMapperPhosphoSitePhosphoSite_ProtMapper | |
| CD4 | PRKCA | P17252 | S | 433 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPProtMapperPhosphoSitePhosphoSite_ProtMapper | |
| CD4 | PRKCQ | Q04759 | S | 433 | phosphorylation | REACH_ProtMapperProtMapper | ProtMapper:19050241 |
Ligand-Receptor Signaling (49)
49 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | OmniPath | No | Yes | No | Yes | No |
| extracellular | extracellular | DGIdb | No | No | No | Yes | No |
| extracellular | extracellular | OmniPath | No | No | No | Yes | No |
| intracellular | intracellular | LOCATE | No | No | No | Yes | No |
| intracellular | intracellular | ComPPI | No | No | No | Yes | No |
| intracellular | intracellular | GO_Intercell | No | No | No | Yes | No |
| intracellular | intracellular | OmniPath | No | No | No | Yes | No |
| cell_adhesion | cell_adhesion | Cellinker | Yes | Yes | No | Yes | No |
| adhesion | adhesion | OmniPath | Yes | Yes | No | Yes | No |
| cell_adhesion | cell_adhesion | OmniPath | Yes | Yes | No | Yes | No |
Regulatory Interaction Network (64)
64 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| COMPLEX:CHEBI:166824_CHEBI:53000_P04440_P06340 | CD4 | P01730 | Yes | Yes | No | SIGNOR | SIGNOR:31001252 | |
| COMPLEX:CHEBI:166824_CHEBI:53000_P05538_P20036 | CD4 | P01730 | Yes | Yes | No | SIGNOR | SIGNOR:31001252 | |
| COMPLEX:CHEBI:166824_CHEBI:53000_P01906_P04440 | CD4 | P01730 | Yes | Yes | No | SIGNOR | SIGNOR:31001252 | |
| KPCA | P17252 | CD4 | P01730 | Yes | No | No | phosphoELM_MIMPPhosphoSite_MIMPMIMPPhosphoSite_norefiPTMnetProtMapperPhosphoSitePhosphoSite_ProtMapper | PhosphoSite:1674746PhosphoSite:15494497 |
Page 7 of 7Previous
Protein Complex Composition (27)
27 records.
| Component Name | Component Gene Symbols | Component UniProt ID | Stoichiometry | Database | Database IDs | References |
|---|---|---|---|---|---|---|
| HDGFPDCD4 | P51858Q53EL6 | 0:0 | hu.MAP2 | |||
| NR1H2PDCD4 | P55055Q53EL6 | 0:0 | Havugimana2012 | Havugimana2012:C_14 | ||
| EIF4A1PDCD4 | P60842Q53EL6 | 4:2 | PDB | PDB:2zu6 | ||
| CD47 | Q08722 | 4 | PDB | PDB:8rp8PDB:5iwlPDB:8zcaPDB:7wn8PDB:7myzPDB:2vscPDB:5tztPDB:4kjy | ||
| CAPRIN1PDCD4 | Q14444Q53EL6 | 0:0 | hu.MAP2 | |||
| BRIP1CERS6GOLGA5PKDCCPOMKSLC35F2TLCD4TMEM120AUSP30 | Q504Y2Q6ZMG9Q70CQ3Q8IXU6Q8TBA6Q96MV1Q9BX63Q9BXJ8Q9H5K3 | 0:0:0:0:0:0:0:0:0 | hu.MAP2 | |||
| PDCD4 | Q53EL6 | 2 | PDB | PDB:2rg8PDB:3eij |
Page 3 of 3Previous
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential UltracentrifugationSize Exclusion Chromatography | Western blotting | 1 | 30646616 |
Sequence, Structure & Domains10
Sequences
Length
458
Mass
51,111
Sequence
MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI
3D Structural Models
Turn
75..79
Helix
84..89; 101..103; 176..178; 398..421; 432..438
Beta Strand
27..32; 37..39; 44..47; 51..55; 56..58; 60..63; 68..71; 94..96; 105..111; 114..128; 131..134; 135..137; 139..144; 152..156; 158..160; 162..172; 180..188; 191..199; 200..202; 426..428; 440..442
3D Structure
Electron microscopy (29); NMR spectroscopy (3); X-ray crystallography (50)
Domain & Motif Annotations
Domain (CC)
The Ig-like V-type domain mediates the interaction with MHCII.
Domain (FT)
26..125; Ig-like V-type; 126..203; Ig-like C2-type 1; 204..317; Ig-like C2-type 2; 318..374; Ig-like C2-type 3
Region
427..455; HIV-1 Vpu-susceptibility domain
Clinical Relevance9
Disease Involvement
FDA approved drug targets
Related Diseases (10)
Biomarker
Phase 3; Phase 2; Approved; Phase 1; Discontinued in Phase 2; Investigative
Drug Targets
FDA approved drug targets
Drugs (16)
Interaction Protein
ENSG00000182866
Interaction Count
1
Interaction Dataset
intact_biogrid
Supporting Publications5
| PMID | Title | Abstract |
|---|---|---|
| 36982991 | Extracellular Vesicles of COVID-19 Patients Reflect Inflammation, Thrombogenicity, and Disease Severity. | Severe patients' EVs displayed higher percentages of small EVs (<150 nm) with increased expression of exosome marker CD63. |
| 37499326 | Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage. | Herein, we investigated the effect of PD-L1 carried on exosomes derived from tumor cells (TEXs) on the aTreg-M2 positive feedback loop, as well as their role in mediating immunosuppression. |
| 37531777 | Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway. | Herein, multifunctional hybrid exosomes for cGAS/STING activation are designed by fusing genetically engineered exosomes carrying CD47 derived from tumor cells with exosomes from M1 macrophages, which are further encapsulated with DNA-targeting agent (SN38) and STING-agonist (MnO Copyright © 2023 Elsevier Ltd. All rights reserved. |
| 37612209 | Mechanism of exosomes from adipose-derived mesenchymal stem cells on sepsis-induced acute lung injury by promoting TGF-β secretion in macrophages. | No abstract available |
| 38902710 | Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer. | Circulating exosomes were collected from serum collected from 30 LCa patients and 20 healthy volunteers by the use of antibody affinity method exploiting CD63 specific surface marker. |